ALBANY, N.Y., Feb. 4, 2016 /PRNewswire/ -- AMRI
(NASDAQ: AMRI) today announced that Anthony J. Maddaluna, Executive Vice President
of Pfizer Inc. and President of Pfizer Global Supply, has been
elected to the AMRI Board of Directors, effective as of
February 4, 2016. In addition, the
Company announced that Mr. Gabe
Leung, a director and member of the audit committee since
2010, has retired from the AMRI Board of Directors in order to
devote further time and attention to his other business
ventures.
"Tony is a terrific addition to our Board of Directors, and we
are extremely pleased to bring his extensive and valuable global
pharmaceutical expertise to AMRI," said William S. Marth, President and CEO. "We believe
Tony's insights and counsel will be very beneficial for
AMRI as we look to further expand our differentiated service
offerings and serve as a strategic outsourcing resource for our
customers.
I would like to thank Gabe for his dedicated service to AMRI
over the last 5 years. His expertise in the pharmaceutical
industry has been a tremendous asset to us and I appreciate his
enthusiasm and counsel as we've transformed AMRI into an integrated
contract research, development and manufacturing company. We wish
him all the best in his future endeavors."
Tony's career with Pfizer spans more than 40 years. He joined
Pfizer in 1975 in St. Louis,
Missouri, serving in the Minerals, Pigments and Metals (MPM)
division in several positions, including Production Supervisor.
From 1978 to 1983, he held various engineering positions in the
Adams, Massachusetts, MPM division
and subsequently worked in the Pharmaceutical division as Manager,
Technical Training. In 1985, Tony relocated to Terre Haute, Indiana, where he held various
positions before becoming Plant Manager. In 1994, he moved to
Pfizer's Barceloneta, Puerto Rico
plant as General Manager. He was named Vice President/Team Leader,
Europe in 1998 and also had
responsibility for Global Logistics, Global Operations Team and
Strategic Planning during a portion of this time. He was named Vice
President, Strategy & Supply Network Transformation in 2008,
and Senior Vice President in 2009. Tony was named to his current
position at Pfizer in 2011. Before joining Pfizer, Tony worked at
the U.S. Environmental Protection Agency and at Johnson &
Johnson as an engineer. Tony represents Pfizer on the National
Association of Manufacturers (NAM) and is a member of the NAM
Executive Committee. Tony holds a B.S. in Chemical Engineering from
Northeastern University and an M.B.A.
in Management and Organization Development from Southern Illinois University.
"I am honored to be appointed to AMRI's Board of Directors,"
said Anthony J.
Maddaluna. "AMRI has established itself as an
innovative force and a rapidly growing CRO/CDMO within the
pharmaceutical outsourcing services industry, and I'm eager to
contribute to the Company's continued growth."
About AMRI
Albany Molecular Research
Inc. (AMRI) is a global contract research and manufacturing
organization that has been working with the Life Sciences industry
to improve patient outcomes and the quality of life for more than
two decades. With locations in North
America, Europe and Asia, our key business segments
include Discovery and Development Services (DDS), Active
Pharmaceutical Ingredients (API), and Drug Product Manufacturing
(DPM). Our DDS segment provides comprehensive services from hit
identification to IND, including expertise with diverse chemistry,
library design and synthesis, in vitro biology and pharmacology,
drug metabolism and pharmacokinetics, as well as natural products.
API supports the chemical development and cGMP manufacture of
complex API, including potent, controlled substances, steroids,
hormones, cytotoxic compounds and sterile API. DPM supports
development through commercial scale production of complex
liquid-filled and lyophilized parenterals, sterile suspensions and
ophthalmic formulations.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-appoints-anthony-j-maddaluna-to-board-of-directors-300215487.html
SOURCE AMRI